TrialNature communications2021

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Maria Gonzalez-Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.